{
  "release_id": "a25293eeae6350fb",
  "id": "cardio:pcsk9-inhibitors",
  "owner": "cardio",
  "kind": "drug",
  "slug": "pcsk9-inhibitors",
  "name": "PCSK9 inhibitors",
  "aliases": [
    "Proprotein convertase subtilisin kexin type 9 inhibitors"
  ],
  "atlases": [
    "cardio"
  ],
  "summary_plain": "PCSK9 inhibitors are cholesterol medicines that block a protein called PCSK9. MedlinePlus says this helps the liver remove and clear LDL cholesterol from the blood. The US labels of alirocumab and evolocumab each call the product a PCSK9 inhibitor, and both have their own pages. A third cholesterol medicine acts on the messenger RNA for PCSK9 instead and is linked here, not filed under the class. This is the class page.",
  "summary_technical": "Class page. MeSH descriptor D000091362 (PCSK9 Inhibitors, lastUpdated 2022-01-01) is an exact match; its scope note says these agents inhibit the PCSK9 enzyme, which has an important role in degrading LDL receptors, and that they favor LDL catabolism and lower plasma LDL cholesterol. The US labels read for alirocumab (BLA125559) and evolocumab (BLA125522) call each product a PCSK9 inhibitor, and RxClass lists the established pharmacologic class PCSK9 Inhibitor on US drug labels for both (read 2026-11-18); alirocumab and evolocumab are filed under this page on that evidence. The US label of a third PCSK9-directed medicine (NDA214012), a small interfering RNA, says it directs breakdown of the mRNA for PCSK9, and RxClass returned no class for it, so it has a related link only. MedlinePlus names these medicines together with another cholesterol class that has its own page. No trial result and no dose is recorded.",
  "editorial_state": "draft",
  "last_substantive_edit": "2026-11-18",
  "last_evidence_check": "2026-11-18",
  "next_review_due": "2027-05-18",
  "identifiers": [
    {
      "scheme": "mesh",
      "value": "D000091362",
      "normalized_value": "D000091362",
      "match": "exact",
      "version": "id.nlm.nih.gov linked data, retrieved 2026-11-18",
      "label": null,
      "from_source": false
    }
  ],
  "navigation": {
    "cardio": {
      "system": [
        "metabolism"
      ],
      "condition-area": [
        "risk-and-prevention",
        "coronary-and-vascular-disease"
      ]
    }
  },
  "payload": {
    "level": "class",
    "mechanism": "MedlinePlus says these medicines block a protein called PCSK9, which helps the liver remove and clear LDL cholesterol from the blood; MeSH says they favor LDL catabolism and lower plasma LDL cholesterol."
  },
  "content_digest": "00f20ae3bab6714ae2340cf5380f759c81f3889640244a3657f39ef375a337a1",
  "review": {
    "content_digest": "00f20ae3bab6714ae2340cf5380f759c81f3889640244a3657f39ef375a337a1",
    "current": [],
    "conflicting": [],
    "stale": [],
    "inactive": []
  },
  "claims": [],
  "decisions": [],
  "milestones": [],
  "relationships": {
    "outgoing": [
      {
        "predicate": "part_of",
        "label": "Files under this front",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:front-medicines",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "targets",
        "label": "MeSH: agents that inhibit PCSK9",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:pcsk9",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:mesh-scope-d000091362-2026-11-18",
          "locator": "scopeNote.@value"
        },
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MedlinePlus lists PCSK9 inhibitors among cholesterol medicines",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:hypercholesterolemia",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MeSH and MedlinePlus: PCSK9 inhibitors lower LDL cholesterol",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:high-ldl-cholesterol",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MedlinePlus names familial hypercholesterolemia where it discusses PCSK9 inhibitors",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:familial-hypercholesterolemia",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "MedlinePlus names a PCSK9 inhibitor and a statin together",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:statins",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "related_to",
        "label": "Acts on the messenger RNA for PCSK9 (label wording); not filed under this class",
        "clinical_claim_not_fact": false,
        "family": "navigation",
        "other_entity_id": "cardio:inclisiran",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": null,
        "primary": false,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ],
    "incoming": [
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:alirocumab",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-1659152-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[2].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      },
      {
        "predicate": "subtype_of",
        "label": "Has subtype",
        "clinical_claim_not_fact": false,
        "family": "sourced",
        "other_entity_id": "cardio:evolocumab",
        "other_entity_in_atlas": true,
        "claim_id": null,
        "evidence": {
          "snapshot_id": "cardio:rxclass-1665684-2026-11-18",
          "locator": "rxclassDrugInfoList.rxclassDrugInfo[2].rxclassMinConceptItem.className"
        },
        "primary": true,
        "role": null,
        "valid_from": null,
        "valid_to": null
      }
    ]
  },
  "page_path": "drugs/pcsk9-inhibitors/",
  "context_path": "api/v1/context/cardio--pcsk9-inhibitors.md"
}
